Two Sigma Investments, LP Myovant Sciences Ltd. Transaction History

Two Sigma Investments, LP

$42.3 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $2.46 Million - $2.77 Million	102,374 Added 352.7%	131,400 $3.54 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $336,701 - $593,291	29,026 New	29,026 $521,000
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $132,431 - $250,053	-17,022 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $193,710 - $279,160	17,022 New	17,022 $227,000
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $645,896 - $1.08 Million	-45,136 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $854,875 - $1.22 Million	45,136 New	45,136 $1.01 Million
Q2 2021 Aug 16, 2021	SELL	$17.07 - $24.56 $631,538 - $908,646	-36,997 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $211,331 - $260,084	10,329 Added 38.73%	36,997 $761,000
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $39,357 - $78,772	2,852 Added 11.98%	26,668 $737,000
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $1.85 Million - $2.97 Million	-131,450 Reduced 84.66%	23,816 $335,000
Q2 2020 Aug 14, 2020	SELL	$7.34 - $20.84 $394,231 - $1.12 Million	-53,710 Reduced 25.7%	155,266 $3.2 Million
Q1 2020 May 15, 2020	BUY	$6.55 - $14.76 $993,196 - $2.24 Million	151,633 Added 264.43%	208,976 $1.58 Million
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $42,546 - $194,597	-10,130 Reduced 15.01%	57,343 $890,000
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $38,784 - $70,694	7,473 Added 12.46%	67,473 $351,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $521,399 - $1.5 Million	60,000 New	60,000 $543,000
Q4 2018 Feb 14, 2019	SELL	$15.01 - $25.2 $113,970 - $191,343	-7,593 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.33 - $26.78 $146,772 - $203,340	7,593 New	7,593 $202,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account